Leadless Pacemaker Fusion Timing via Extracardiac Signal Monitoring
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
The absence of an intracardiac lead in leadless cardiac pacemakers (LCPs) makes it difficult to detect atrial events for cardiac resynchronization therapy (CRT), as P-wave detection by extracardiac devices like subcutaneous cardiac monitors (SCMs) can be challenging due to variability and difficulty in sensing.
Innovation Solution
An LCP is configured to provide pacing therapy at predetermined intervals, and the morphology of resulting cardiac electrical signals is monitored by an extracardiac device to determine desirable fusion beats, with communication to adjust pacing intervals to ensure repeatable fusion, using a subcutaneous implantable defibrillator (SICD) or SCM to modify pacing timing.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Object-affected harmful factors
If an LCP is used to provide pacing therapy, then device simplicity and reduced morbidity are improved, but the ability to detect atrial events for CRT timing is worsened
Solution Approach 1:
An extracardiac device (SCM or SICD) serves as an intermediary to detect atrial events via P-wave sensing and communicate timing information to the LCP, enabling CRT without requiring the LCP to have direct atrial sensing capability
Solution Approach 2:
The extracardiac device performs multiple functions including P-wave detection, timing information processing, and communication with the LCP, consolidating capabilities that would otherwise require separate components
2Difficulty of detecting and measuring
If P-wave detection is used for CRT timing, then atrial event detection is improved, but detection reliability is worsened due to variability and difficulty in sensing
Solution Approach 1:
The system continuously monitors cardiac electrical signals and adjusts pacing intervals based on detected fusion beat quality, using feedback loops to maintain reliable CRT timing despite variable P-wave detection conditions
3Productivity
If fusion beats are monitored to adjust pacing intervals, then CRT efficacy is improved, but device complexity is worsened
Solution Approach 1:
The extracardiac device leverages its existing signal processing capabilities to analyze fusion beat morphology and automatically adjust pacing intervals, making the system self-regulating without requiring additional dedicated monitoring hardware
Data Source
Figure 1
Figure 2
Figure 3
AI summary
Methods, systems and devices for providing cardiac resynchronization therapy (CRT) to a patient using a Ieadless cardiac pacemaker and an extracardiac device. The extracardiac device is configured to analyze one or more QRS complexes of the patient's heart, determine whether fusion pacing is taking place, and, if not, to communicate with the Ieadless cardiac pacemaker to adjust intervals used in the CRT in order to generate desirable fusion of the pace and intrinsic signals. The extracardiac device may take the form of a subcutaneous implantable monitor, a subcutaneous implantable defibrillator, or other devices including wearable devices.